---
title: "Composite Patient Profiling Predicts Blood Pressure Response in the VALUE Trial"
id: "medrxiv-15-patient-profiling-and-outcome-of-antihypertensive-treatment-an-exploratory"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-patient-profiling-and-outcome-of-antihypertensive-treatment-an-exploratory"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.18.26363450v1?rss=1"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Composite Patient Profiling Predicts Blood Pressure Response in the VALUE Trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-patient-profiling-and-outcome-of-antihypertensive-treatment-an-exploratory
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.18.26363450v1?rss=1)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preprint reanalysed data from the double-blinded **VALUE trial** (n=15,313) to test whether combined patient characteristics better predict response to antihypertensive therapy than single factors. - Investigators divided the cohort into an exploratory set (two thirds) and a validation set (one third) to build and test composite profiles. - Four established predictors were combined to form composite profiles: **age**, **severity of hypertension**, **comorbidity**, and previous treatment status. - Logistic regression showed that **BP control** rates differed significantly across profiles (likelihood ratio test P<0.001), and results from the exploratory cohort reproduced in the validation cohort. - Composite profiling predicted BP control significantly better than any single predictor (P<0.001 for all comparisons). - Profiles were also significantly associated with incidence of cardiovascular events; adverse event rates did not vary by profile. - The authors conclude composite patient profiles may better identify who is more or less likely to achieve BP control and could help individualize antihypertensive therapy. - The report is a preprint and not peer reviewed; trial registration ID is not available because the VALUE trial predated trial registries. - Competing interests from several authors are disclosed; data will be available on reasonable request after publication. - All reported methods and results are exploratory secondary analyses of an existing randomized outcome trial and should not yet change clinical practice.
## Clinical Analysis & Structured Key Points
PATIENT PROFILING AND OUTCOME OF ANTIHYPERTENSIVE TREATMENT. An Exploratory Analysis of the VALUE Trial. | medRxiv Skip to main content PATIENT PROFILING AND OUTCOME OF ANTIHYPERTENSIVE TREATMENT. An Exploratory Analysis of the VALUE Trial. View ORCID Profile Peter W. de Leeuw , View ORCID Profile Camilla L. Söraas , View ORCID Profile Giuseppe Mancia , View ORCID Profile Maria H. Mehlum , Kenneth A. Jamerson , Solko W Schalm , View ORCID Profile Sverre E. Kjeldsen , View ORCID Profile Michael Weber doi: https://doi.org/10.64898/2026.09.18.26363450 Peter W. de Leeuw 1 Maastricht University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Peter W. de Leeuw For correspondence: p.deleeuw48{at}kpnmail.nl Camilla L. Söraas 2 Oslo University Hospital, Ullevaal; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Camilla L. Söraas Giuseppe Mancia 3 University of MIlano-Bicocca, Dept. of Medicine and Surgey; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Giuseppe Mancia Maria H. Mehlum 4 Oslo University Hospital and University of Oslo; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Maria H. Mehlum Kenneth A. Jamerson 5 University of Michigan Health System; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Solko W Schalm 6 Erasmus University Rotterdam; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sverre E. Kjeldsen 7 Oslo University Hospital, Ullevaal and University of Oslo; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sverre E. Kjeldsen Michael Weber 8 SUNY Downstate College of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michael Weber Abstract Info/History Metrics Data/Code Preview PDF Abstract Background Randomized outcome trials have shown the benefit of antihypertensive treatment, but subgroup analyses exploring treatment responses in relation to patient characteristics are usually based on single factors rather than comprehensive patient profiles. We hypothesized that a combination of individual predictors better identifies patients who are more or less likely to achieve blood pressure (BP) control. Methods To test our hypothesis, we reanalysed the data from the double-blinded VALUE-outcome trial (n=15,313). The patient population was divided into an exploratory cohort (2/3) and a validation cohort (1/3). We constructed composite patient profiles by combining four proven predictors of BP control: age, severity of hypertension, comorbidity and previous treatment status. Logistic regression and Cox proportional hazard models were used to test whether BP control and cardiovascular event rates differed among these profiles, and whether profiling conferred additional predictive information beyond the individual factors alone. Results BP control rates differed significantly between patient profiles, regardless of treatment (likelihood ratio test, p<0.001). Results from the exploratory cohort were reproducible in the validation cohort. Profiling predicted BP control significantly better than any individual factor (p<0.001 for all comparisons). In addition, there were significant associations between profiles and the incidence of cardiovascular events. Adverse events, however, were not related to profiles. Conclusions We conclude that composite patient profiles may predict BP responses to antihypertensive treatment more accurately than single factors. These findings may help to better individualize antihypertensive therapy. Competing Interest Statement GM reports honoraria from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini Group, Merck, Novartis, Recordati, Sandoz, Sanofi and Servier outside the present work. SEK reports lecture honoraria from Amgen, Boehringer-Ingelheim, Cadilla, Emcure, Getz, Hikma, JB Pharma, Merck KGaA, Vector-Intas and Zydus. The other authors report no conflicts. MAW reports consulting fees and research services for Janssen, Bristol Myers Squibb, CinCor, Medtronic, ReCor, Novartis, Alnylam, Verve Medical and Ablative Solutions. Clinical Trial This trial was designed and executed before the implementation of Trial Registries. Therefore, no ID is available. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All information is available from the original VALUE investigators. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data will be made available upon reasonable request following publication. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted September 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following PATIENT PROFILING AND OUTCOME OF ANTIHYPERTENSIVE TREATMENT. An Exploratory Analysis of the VALUE Trial. Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share PATIENT PROFILING AND OUTCOME OF ANTIHYPERTENSIVE TREATMENT. An Exploratory Analysis of the VALUE Trial. Peter W. de Leeuw , Camilla L. Söraas , Giuseppe Mancia , Maria H. Mehlum , Kenneth A. Jamerson , Solko W Schalm , Sverre E. Kjeldsen , Michael Weber medRxiv 2026.09.18.26363450; doi: https://doi.org/10.64898/2026.09.18.26363450 Share This Article: Copy Citation Tools PATIENT PROFILING AND OUTCOME OF ANTIHYPERTENSIVE TREATMENT. An Exploratory Analysis of the VALUE Trial. Peter W. de Leeuw , Camilla L. Söraas , Giuseppe Mancia , Maria H. Mehlum , Kenneth A. Jamerson , Solko W Schalm , Sverre E. Kjeldsen , Michael Weber medRxiv 2026.09.18.26363450; doi: https://doi.org/10.64898/2026.09.18.26363450 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Cardiovascular Medicine Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4832) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15980) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7067) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5060) Health Policy (1438) Health Systems and Quality Improvement (1775) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16309) Intensive Care and Critical Care Medicine (1176) Medical Education (671) Medical Ethics (155) Nephrology (727) Neurology (7294) Nursing (369) Nutrition (1084) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1006) Oncology (3616) Ophthalmology (1055) Orthopedics (398) Otolaryngology (458) Pain Medicine (474) Palliative Medicine (139) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5921) Public and Global Health (9772) Radiology and Imaging (2433) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (581) Surgery (782) Toxicology (107) Transplantation (305) Urology (293)
## Related Clinical Research

- [Machine learning and deep learning prediction of hypertension and key risk factors in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-12-machine-learning-and-deep-learning-based-prediction-of-hypertension-and.md)
- [Dyslipidemia care in Japan before and after the 2024 fee revision: nationwide claims analysis](https://medichelpline.com/clinical-feed/plos-one-19-real-world-patterns-of-dyslipidemia-care-before-and-after-a-national-fee.md)
- [Antihypertensive Treatment Gaps in Nigeria: NDHS 2023–24 Machine Learning Analysis of Non‑Uptake](https://medichelpline.com/clinical-feed/medrxiv-3-antihypertensive-pharmacotherapy-gaps-in-nigeria-a-predictive-machine-learning.md)
- [Factors Linked to Adherence to Anti-Hypertensive Medication at a Primary Health Centre in Ndola, Z](https://medichelpline.com/clinical-feed/medrxiv-1-factors-associated-with-adherence-to-anti-hypertensive-medication-among.md)
- [MGST3 marks a mitochondrial-health–linked M2-like macrophage state in atherosclerosis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-7-mgst3-defines-a-mitochondrial-health-associated-m2-macrophage-state-in.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.